Valo SPAC Presentation Deck
Internal supply chain of programs demonstrates impact of Opal drug acceleration,
providing, we believe, validation to scale via external program supply chain
CARDIOVASCULAR-
METABOLIC-RENAL
ONCOLOGY
NEURODEGENERATIVE
TARGET DISCOVERY
OPL-0301¹
OPL-0401²
OPAL-0022
OPAL-0004
OPAL-0018
OPAL-0003
OPL-0101³
OPAL-0021
OPAL-0015
OPAL-0024
OPAL-0001
OPAL-0014
OPAL-0023
OPAL-0012
OPAL-0016
OPAL-0002
OPAL-0006
MOLECULE DISCOVERY
IND ENABLING
Atherosclerosis
Atherosclerosis; Glioblastoma
Atherosclerosis
Heart Failure; Glioblastoma
Heme-Targeting
PHASE I
NSCLC; Squamous Cell Carcinoma; Targeted Defined Tumors
Defined Tumors
Medulla/Glioblastoma Brain Tumors; Breast Cancer
Pancreatic Ductal Adenocarcinoma (PDAC), Targeted Defined Tumors
Defined Tumors; Immune Modulation
NSCLC
Induced Neuropathy and Cardiomyopathy
Neurodegenerative
Neurodegenerative; Oncology (metastatic)
PHASE II
Immuno-Oncology (Platform for broader Immunology)
Post-MI; Acute Kidney Injury
Diabetic Retinopathy;
Diabetic Complications
PLANNED 2021 INTERNAL SUPPLY
CHAIN KEY MILESTONES4
Launching Opal-enabled Phase II study
for OPL-0301
Planning Opal-enabled Phase II study for
OPL-0401 (launch in 2022)
Advancing OPL-0101 IND-enabling
experiments
Advancing 2 internal discovery programs
toward Drug Candidate status
Activating 2 discovery programs pursuing
targets enabled by Opal
PLANNED 2021 EXTERNAL SUPPLY
CHAIN KEY MILESTONES4
Launching strategic ecosystem
partnership program
Increased flywheel velocity through data
and compute expansion
Proprietary programs across cardiovascular-metabolic-renal, oncology, and neurodegenerative disease that use and/or further
build Opal. Additional proprietary preclinical programs with potential for out-licensing or future development.
Valo Pipeline as of May 28, 2021 [1] Valo in-licensed OPL-0301 in February 2021 [2] Valo in-licensed OPL-0401 in May 2021 [3] Valo acquired OPL-0101 in May 2021 [4] Reflects management's 2021 goals.
2Q21
25View entire presentation